LOS ANGELES, CA--(Marketwired - Jan 15, 2015) - BioSig Technologies (
Dr. Asirvatham is a professor of medicine and vice chair of the Division of Cardiovascular Diseases, Department of Medicine, at Mayo Clinic in Rochester, Minnesota, as well as a consultant in cardiac electrophysiology in the Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine. He is also program director for the Clinical Cardiac Electrophysiology Training Program.
Dr. Asirvatham will participate on the Scientific Advisory Board that guides BioSig on the development and implementation of clinical programs in support of its PURE EP System's validation and FDA 510(k) application.
Gregory D. Cash, BioSig's Chief Executive Officer, said, "Dr. Asirvatham is highly regarded as one of the nation's top electrophysiologists, working at one of the world's finest cardiac medicine facilities. His expertise will prove instrumental in advancing PURE EP toward validation and ultimately commercialization. I am delighted to welcome Dr. Asirvatham on BioSig's Scientific Advisory Board."
Samuel J. Asirvatham, M.D. Bio
Samuel J. Asirvatham, M.D., is a professor of medicine and vice chair of the Division of Cardiovascular Diseases, Department of Medicine, at Mayo Clinic in Rochester, Minnesota, as well as a consultant in cardiac electrophysiology in the Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine. He is also program director for the Clinical Cardiac Electrophysiology Training Program.
In addition, Dr. Asirvatham is editor of Circulation: Arrhythmia and Electrophysiology, Section "Teaching Rounds in Clinical Electrophysiology."
After completing medical school at Christian Medical College in Vellore, India, his internship was at Columbia University Hospital in New York City. Following residency and chief residency at the University of Wisconsin-Madison, Dr. Asirvatham did his clinical cardiac and electrophysiology training at the University of Oklahoma in Oklahoma City.
About BioSig Technologies
BioSig is a medical device company that has developed a proprietary technology platform designed to compete in the $3 billion electrophysiology (EP) marketplace that analysts forecast growing at 12.1 percent(1), (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE EP System.
PURE EP is a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets -- areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia).
BioSig intends to seek FDA 510(k) approval for the PURE EP System. The Company has already achieved proof of concept validation through UCLA EP & Animal Labs, and is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA, and Mayo Clinic.
This release includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019